Poland· PL-100485360
Epysqli
A eculizumab product containing eculizumabum, registered in Poland by Samsung Bioepis NL B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Eculizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AJ01 (eculizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Eculizumab · ATC L04AJ01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Eculizumabum
- Manufacturer
- Samsung Bioepis NL B.V.
- Country
- Poland (PL)
- ATC code
- L04AJ01
- ATC class
- Eculizumab
- Defined daily dose
- 64 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin08809593174202
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for eculizumab.
Graded by severity as the source publishes them — 2 minor. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Eculizumab · interactions on record
2 records
Same medicine, other countries
Eculizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumBekemv 300 mgAmgen Europe
- CzechiaBEKEMVAmgen Europe B.V., Breda
- FinlandBEKEMVAmgen Europe B.V.
- IrelandBEKEMV 300 mg Concentrate for solution for infusionAmgen Technology (Ireland) Unlimited Company
- IcelandBekemvAmgen Technology (Ireland) UC*
- NorwayBekemvAmgen Technology Ireland
- SwedenBEKEMV 300 mg Koncentrat till infusionsvätska, lösningAmgen Europe B.V.
- United StatesBKEMVAmgen Inc
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Bekemv, Soliris
- Liechtenstein · Soliris
- Norway · Bekemv, Soliris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bb618c08-6c39-4867-85f0-10752a810738 GET /v1/drugs/bb618c08-6c39-4867-85f0-10752a810738?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "300 mg",
"packaging": "08809593174202 ¦ Rpz ¦ EU/1/23/1735/001 ¦ 150656\n1 fiol. 30 ml",
"substance": "Eculizumabum 300 mg",
"common_name": "Eculizumabum",
"pl_product_id": "100485360",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about eculizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.